iShares Nasdaq Biotechnology ETF (IBB)
118.55
-0.74 -0.62%
NASDAQ
Sep 21, 20:00
Delayed 2m
USD
IBB Key Stats
| Net Asset Value | Upgrade |
| Discount or Premium to NAV | Upgrade |
| Turnover Ratio | Upgrade |
| 1 Year Fund Level Flows | Upgrade |
View All IBB News
IBB News
-
WireHeadlineTime (ET)
-
Yahoo09/21 15:20
-
Yahoo09/21 14:30
-
MT Newswires09/21 13:28
-
MT Newswires09/21 09:23
-
Yahoo09/21 09:09
-
Yahoo09/20 16:55
-
MT Newswires09/20 13:30
-
SA Breaking News09/20 10:26
-
MT Newswires09/20 09:15
-
MT Newswires09/19 13:30
IBB Performance
| Total Return (Price) | Total Return (NAV) | Cat. Total Return (NAV) | % Rank in Cat. (NAV) | |
|---|---|---|---|---|
| 1M | 1.18% | 1.26% | 2.46% | 79 |
| 3M | 5.42% | 5.60% | 6.64% | 69 |
| 6M | 7.27% | 7.38% | 12.37% | 83 |
| YTD | 11.19% | 11.32% | 18.23% | 84 |
| 1Y | 7.68% | 7.84% | 20.05% | 93 |
| 3Y | 1.69% | 1.67% | 9.48% | 93 |
| 5Y | 11.31% | 11.31% | 14.38% | 76 |
| 10Y | 15.75% | 15.77% | 14.38% | 28 |
IBB Asset Allocation
| Type | % Net | % Long | % Short |
|---|---|---|---|
| Cash | 0.15% | 0.15% | 0.00% |
| Stock | 99.85% | 99.85% | 0.00% |
| Bond | 0.00% | 0.00% | 0.00% |
| Convertible | 0.00% | 0.00% | 0.00% |
| Preferred | 0.00% | 0.00% | 0.00% |
| Other | 0.00% | 0.00% | 0.00% |
IBB Region Exposure
| Americas | 97.80% |
| North America | 97.80% |
| Latin America | 0.00% |
| Greater Europe | 1.87% |
| United Kingdom | 0.67% |
| Europe Developed | 1.20% |
| Europe Emerging | 0.00% |
| Africa/Middle East | 0.00% |
| Greater Asia | 0.33% |
| Japan | 0.00% |
| Australasia | 0.00% |
| Asia Developed | 0.00% |
| Asia Emerging | 0.33% |
| Market Classification | |
| % Developed Markets | 99.67% |
| % Emerging Markets | 0.33% |
IBB Stock Sector Exposure
| Basic Materials | 0.00% |
| Communication Services | 0.00% |
| Consumer Cyclical | 0.00% |
| Consumer Defensive | 0.06% |
| Energy | 0.00% |
| Financial Services | 0.00% |
| Healthcare | 99.92% |
| Industrials | 0.00% |
| Real Estate | 0.00% |
| Technology | 0.02% |
| Utilities | 0.00% |
IBB Stock Market Capitalization
| Giant | 16.44% |
| Large | 38.86% |
| Medium | 23.95% |
| Small | 17.75% |
| Micro | 3.00% |
IBB Stock Style Exposure
| Large Cap Value | 21.21% |
| Large Cap Blend | 8.84% |
| Large Cap Growth | 27.62% |
| Mid Cap Value | 0.46% |
| Mid Cap Blend | 3.54% |
| Mid Cap Growth | 20.09% |
| Small Cap Value | 1.00% |
| Small Cap Blend | 3.92% |
| Small Cap Growth | 13.32% |
View More Holdings
As of Sept. 20, 2018
IBB Top 10 Holdings
| Symbol | Name | % Weight | Price | % Chg |
|---|---|---|---|---|
| BIIB | Biogen Inc | 8.45% | 345.41 | +1.22% |
| AMGN | Amgen Inc | 8.31% | 205.10 | +0.00% |
| GILD | Gilead Sciences Inc | 8.08% | 75.51 | +0.91% |
| CELG | Celgene Corp | 7.55% | 87.72 | -0.66% |
| ILMN | Illumina Inc | 6.18% | 358.16 | +0.52% |
| REGN | Regeneron Pharmaceuticals Inc | 4.69% | 390.28 | +0.78% |
| VRTX | Vertex Pharmaceuticals Inc | 4.27% | 180.08 | -0.24% |
| ALXN | Alexion Pharmaceuticals Inc | 3.35% | 121.99 | -2.10% |
| MYL | Mylan NV | 2.41% | 38.99 | +0.67% |
| BMRN | Biomarin Pharmaceutical Inc | 2.14% | 97.84 | -2.55% |
Advertisement
IBB One Page Reports
- One Page Report Download
IBB Basic Info
| Style | |
|---|---|
| Equity Style | Large Cap/Growth |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | iShares |
| Benchmark Index | |
|---|---|
NASDAQ Biotechnology TR USD |
100.0% |
IBB Manager Info
| Name | Tenure |
|---|---|
| Alan Mason | 2.30 yrs |
| Amy Whitelaw | 0.00 yrs |
| Diane Hsiung | 10.59 yrs |
| Greg Savage | 10.59 yrs |
| Jennifer Hsui | 6.00 yrs |
| Rachel Aguirre | 0.00 yrs |
IBB Net Fund Flows
| 1M | -118.29M |
| 3M | 68.64M |
| 6M | -489.65M |
| YTD | -1.289B |
| 1Y | -829.08M |
| 3Y | 787.97M |
| 5Y | 2.625B |
| 10Y | 2.780B |
IBB Risk Info
| Beta (5Y) | 1.240 |
| Max Drawdown (All) | 62.85% |
| Historical Sharpe (10Y) | 0.8743 |
| Historical Sortino (All) | 0.6056 |
| 30-Day Rolling Volatility | 13.61% |
| Daily Value at Risk (VaR) 1% (All) | 4.83% |
| Monthly Value at Risk (VaR) 1% (All) | 19.37% |
IBB Fundamentals
| Dividend Yield TTM (9-21-18) | 0.27% |
| SEC Yield (4-30-18) | 0.13% |
| Weighted Average PE Ratio | 31.34 |
| Weighted Average Price to Sales Ratio | 6.594 |
| Weighted Average Price to Book Ratio | 5.775 |
| Weighted Median ROE | 5.07% |
| Weighted Median ROA | -2.92% |
| Forecasted Dividend Yield | 0.54% |
| Forecasted PE Ratio | 16.90 |
| Forecasted Price to Sales Ratio | 5.509 |
| Forecasted Price to Book Ratio | 4.145 |
| Number of Holdings | 193 |
IBB Growth Estimates
| Forecasted 5 Yr Earnings Growth | 13.61% |
| Forecasted Book Value Growth | 13.91% |
| Forecasted Cash Flow Growth | 2.92% |
| Forecasted Earnings Growth | -12.17% |
| Forecasted Revenue Growth | 11.37% |
IBB Attributes
| Key Dates | |
|---|---|
| Inception Date | 2/5/2001 |
| Termination Date | |
| Last Annual Report Date | 3/31/2018 |
| Last Prospectus Date | 6/26/2018 |
| Attributes | |
| Exchange Traded Share | Yes |
| Exchange Traded Note | No |
| Enhanced Index Fund | No |
| Fixed Distribution Fund | No |
| High-Net Worth Individual Fund | No |
| Index Fund | Yes |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | Yes |
| Socially Responsible Fund | No |
| General Availability | |
| Available for Insurance Product | No |
| Available for Retirement Plan | No |
| Available for RRSP | No |
IBB Excel Add-In Codes
- Name: =YCI("IBB","name")
- Broad Asset Class: =YCI("IBB", "broad_asset_class")
- Broad Category: =YCI("IBB", "broad_category_group")
- Prospectus Objective: =YCI("IBB", "prospectus_objective")
To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.
Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.
Advertisement
